Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
This section highlights volatility metrics for the dividend aristocrats ETF, offering key indicators to monitor risk and potential entry points.
22,062 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
A surge in wealth and demand for luxury goods in the Middle East is shadowed by Iran-related conflict risks, with Ber...
A quiet road, a moment of confusion, and a spotlight on money. This piece translates a high-profile misstep into acti...
Gas prices climb as policy gains from the One Big Beautiful Bill Act spark optimism. Economists warn the higher fuel ...
Riverside County Sheriff Chad Bianco, a Republican candidate for California governor, says he seized ballots tied to ...
Monero's XMR remains in a tight range around the mid-$180s as liquidity thins. Analysts say the trapped setup could f...
Lumentum’s stock surged 1,000% over the past year as AI-driven demand for high-power lasers accelerates. A BNP Pariba...
A new anti-spam proposal at the heart of Bitcoin’s governance debate has sparked a power struggle, with analysts ques...
A leading AI investor says up to 80% of jobs could be AI-enabled by 2030, a view that’s fueling a new wave of policy ...
A high-profile musician argues that wealth isn’t a character flaw. This piece translates that stance into practical p...
The White House rejected Elon Musk’s public offer to fund TSA salaries during the budget stalemate, setting off a fre...
As market conditions shift in 2026, many 401(K) accounts look solid on paper but lag in real terms. This report highl...